… delivery of drug in the bladder for treatment of bacillus … no longer as adjunct to statin therapy)  Repatha (evolocumab)— … sublineage LP.8.1 Actemra (tocilizumab)— Indication for … illness in vaccine recipients; Vimkunya (chikungunya recombinant, vaccine) is …

… progress in broadening treatment options, improving affordability … Pharmaceuticals) received FDA approval as a biosimilar to ustekinumab (Stelara; Janssen Biotech … by phase 3 trial data in … a biosimilar referencing tocilizumab (Actemra; Genentech) in both …

… Medical College of Wisconsin in Milwaukee. LOTIS-7 Trial Design Emerging trials … by the FDA and European Medicines Agency for … antipyretics, requiring tocilizumab (Actemra) less frequently than … -drug conjugate loncastuximab tesirine for the treatment of …

… . Four patients received tocilizumab (Actemra) for CRS. Notably, no … Hospital of the Naval Medical University in China. How … end point in both trials. Secondary end points included … respectively. The most common treatment-emergent adverse effects in the …

… a large unmet medical need; promoting domestic drug development and manufacturing … . Regarding safety, any-grade treatment-emergent adverse effects (TEAEs) … prophylactic tocilizumab (Actemra) was given, per trial protocol. References FDA proactively awards …

… phase 2 EPCORE DLBCL-3 trial (NCT05660967 ) indicated that single-agent … were treated with either tocilizumab (Actemra; 29%) or corticosteroids (14%), leading … announces data from multiple clinical trials showing treatment with fixed-duration epcoritamab …

… 2024 were specialty drugs.1 As medication experts, pharmacists … treatments are beremagene geperpavec-svdt (Vyjuvek; Krystal Biotech), … pemphigoid. In clinical trials, treatment with dupilumab resulted in … to access specialty pharmaceuticals in the safest, …

… pharmacy and treatment centers to hold a drug called tocilizumab [Actemra] onsite so … reporting of toxicities to the FDA should they occur after CAR … administration of these treatments…. Initially, we interfaced with the FDA through its …

… cancer drug Rituxan and anti-inflammatory Actemra offset shortfalls … treatments as well as heavy investments in experimental obesity drugs … 4 billion francs. Pharmaceutical division sales for the … biotech unit Genentech plans to offer influenza antiviral pill …

… FDA approvals of axi-cel and liso-cel affected the LBCL treatment … phase 3 ZUMA-7 trial [NCT03391466] population with … received treatment for these complications, including tocilizumab [Actemra], steroids … in the [clinical trials]. The median duration …